Chemotherapy for Testicular Cancer

  • Thomas R. Geldart
  • Graham M. Mead


The last 30 years have seen extraordinary advances in the management of metastatic germ cell cancer of the testis. Prior to the advent of cisplatin-containing chemotherapy in the mid-1970s, chemotherapy was highly toxic, and gave poor results, with cure unusual in those with advanced disease. Following the introduction of cisplatin, and subsequently etoposide, progress has been rapid, not least in the development of ancillary drugs (e.g., 5- hydroxytryptamine [5-HT3] antagonists and growth factors). Modern therapy is now usually curative, tolerable, and has few long-term side effects. Indeed, the current dearth of randomized trials for most subgroups of these patients is largely a testimony to the advances taking place during this period.


Clin Oncol Testicular Cancer Urologic Cancer Germ Cell Cancer Nonseminomatous Germ Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15(2):594–603.Google Scholar
  2. 2.
    Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87(3):293–298.PubMedGoogle Scholar
  3. 3.
    Peckham MJ, Barrett A, Liew KH, et al. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cisplatin (BEP). Br J Cancer 1983;47(5):613–619.PubMedGoogle Scholar
  4. 4.
    Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316(23):1435–1440.PubMedCrossRefGoogle Scholar
  5. 5.
    Horwich A, Dearnaley DP, A’Hern R, et al. The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 1992;28A(8–9):1307–1310.PubMedCrossRefGoogle Scholar
  6. 6.
    Schmoll HJ, Harstrick A, Bokemeyer C, et al. Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 1993;72(1):237–243.PubMedCrossRefGoogle Scholar
  7. 7.
    Childs WJ, Nicholls EJ, Horwich A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 1992;3(4):291–296.PubMedGoogle Scholar
  8. 8.
    Horwich A, Oliver RT, Wilkinson PM, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer 2000;83(12):1623–1629.PubMedCrossRefGoogle Scholar
  9. 9.
    Clemm C, Bokemeyer C, Gerl A, et al. Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 2000:326a.Google Scholar
  10. 10.
    Bokemeyer C, Kollmannsberger C, Flechon A, et al. Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. Proc Am Soc Clin Oncol 2002;19:186a.Google Scholar
  11. 11.
    Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993;11(4):598–606.PubMedGoogle Scholar
  12. 12.
    Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844–1852.PubMedGoogle Scholar
  13. 13.
    Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997;15(7):2553–2558.PubMedGoogle Scholar
  14. 14.
    de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15(5):1837–1843.PubMedGoogle Scholar
  15. 15.
    Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13(2):470–476.PubMedGoogle Scholar
  16. 16.
    Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7(3):387–391.PubMedGoogle Scholar
  17. 17.
    Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol 1998;16(2):702–706.PubMedGoogle Scholar
  18. 18.
    de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19(6):1629–1640.PubMedGoogle Scholar
  19. 19.
    Fossa SD, de Wit R, Roberts JT, et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003;21(6):1107–1118.PubMedCrossRefGoogle Scholar
  20. 20.
    Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001;357(9258):739–745.PubMedCrossRefGoogle Scholar
  21. 21.
    Culine S, Kerbrat P, Bouzy J, et al. The optimal chemotherapy regimen for good-risk metastatic non seminomatous germ cell tumours (MSNGCT) is 3 cycles of bleomycin, etoposide and cisplatin. Mature results of a randomized trial. Proc Am Soc Clin Oncol 2003;22:382.Google Scholar
  22. 22.
    Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9(7):1163–1172.PubMedGoogle Scholar
  23. 23.
    Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16(4):1287–1293.PubMedGoogle Scholar
  24. 24.
    Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003;97(8):1869–1875.PubMedCrossRefGoogle Scholar
  25. 25.
    Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16(2):692–701.PubMedGoogle Scholar
  26. 26.
    Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16(2):716–724.PubMedGoogle Scholar
  27. 27.
    Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839–846.PubMedCrossRefGoogle Scholar
  28. 28.
    Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997;15(7):2546–2552.PubMedGoogle Scholar
  29. 29.
    Bokemeyer C, Schmoll HJ, Harstrick A, et al. A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer 1993;29A(16):2225–2231.PubMedCrossRefGoogle Scholar
  30. 30.
    Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003;21(22):4083–4091.PubMedCrossRefGoogle Scholar
  31. 31.
    Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997;8(5):477–483.PubMedCrossRefGoogle Scholar
  32. 32.
    Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003;21(5):871–877.PubMedCrossRefGoogle Scholar
  33. 33.
    Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987;2(8554):294–298.PubMedCrossRefGoogle Scholar
  34. 34.
    Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10(11):1762–1768.PubMedGoogle Scholar
  35. 35.
    Bohlen D, Borner M, Sonntag RW, Fey MF, Studer UE. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999;161(4):1148–1152.PubMedCrossRefGoogle Scholar
  36. 36.
    Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992;148(5):1453–1455;discussion 1455–1456.PubMedGoogle Scholar
  37. 37.
    Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996;14(2):441–448.PubMedGoogle Scholar
  38. 38.
    Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996;14(4):1106–1113.PubMedGoogle Scholar
  39. 39.
    Abratt RP, Pontin AR, Barnes RD, Reddi BV. Adjuvant chemotherapy for stage I non-seminomatous testicular cancer. S Afr Med J 1994;84(9):605–607.PubMedGoogle Scholar
  40. 40.
    Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. J Urol 2000;163(6):1785–1787.PubMedCrossRefGoogle Scholar
  41. 41.
    Warde P, Gospodarowicz MK, Banerjee D, et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997;157(5):1705–1709;discussion 1709–1710.PubMedCrossRefGoogle Scholar
  42. 42.
    Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17(4):1146.PubMedGoogle Scholar
  43. 43.
    Jones WG, Fossa SD, Mead GM, et al. A randomised trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE18). Eur J Cancer 2001;37(suppl 6):S157.CrossRefGoogle Scholar
  44. 44.
    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk follow-ing testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11(3):415–424.PubMedGoogle Scholar
  45. 45.
    Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 1997;33(2):253–262.PubMedCrossRefGoogle Scholar
  46. 46.
    Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000;55(1):102–106.PubMedCrossRefGoogle Scholar
  47. 47.
    Aparicio J, Garcia del Muro X, Maroto P, et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867–872.PubMedCrossRefGoogle Scholar
  48. 48.
    Krege S, Kalund G, Otto T, Goepel M, Rubben H. Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma. Eur Urol 1997;31(4):405–407.PubMedGoogle Scholar
  49. 49.
    Oliver RT, Edmonds PM, Ong JY, et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: pp should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys 1994;29(1):3–8.PubMedGoogle Scholar
  50. 50.
    Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997;15(1):239–245.PubMedGoogle Scholar
  51. 51.
    Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001;91(7):1297–1303.PubMedCrossRefGoogle Scholar
  52. 52.
    O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14(1):91–96.PubMedCrossRefGoogle Scholar
  53. 53.
    Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8):1513–1523.PubMedCrossRefGoogle Scholar
  54. 54.
    Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18(8):1725–1732.PubMedGoogle Scholar
  55. 55.
    Travis LB, Andersson M, Gospodarowicz M, et al. Treatmentassociated leukemia following testicular cancer. J Natl Cancer Inst 2000;92(14):1165–1171.PubMedCrossRefGoogle Scholar
  56. 56.
    Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14(11):2923–2932.PubMedGoogle Scholar
  57. 57.
    Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77(8):1355–1362.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Thomas R. Geldart
    • 1
  • Graham M. Mead
    • 1
  1. 1.Department of Medical Oncology Southampton General HospitalCancer Care DirectorateSouthamptonUK

Personalised recommendations